Webinar: Wearable Bolus Injectors
Balancing Stakeholder Needs and Overcoming Barriers to Entry
Join the Webinar On-demand
Until now, biologics and immuno-oncology drugs have tended to fall into two very different delivery modalities; 1 to 2 mL self-administered injection using devices such as autoinjectors and 10 mL+ infusion delivery typically administered by healthcare professionals in a hospital or outpatient setting. However, more and more, pharmaceutical companies are formulating (or re-formulating) drugs that fall into the gap between these modalities in the drive to move the delivery of higher-volume biologics away from the clinic and towards a home-based, self-administered environment.
Although the number of commercially available on-body delivery systems remains low, several companies have devices in development to help fill this gap, including the recent collaboration announced between Phillips-Medisize and Subcuject. However, the market for such devices remains immature and faces persistent challenges from well-established autoinjectors and a new cohort of larger payload, more sustainable autoinjector variants.
Register for an upcoming webinar to hear Tony Bedford, Director of Front-end Innovation for Phillips-Medisize, a Molex company, discuss some of the challenges of developing a wearable bolus injector. To successfully achieve product development, the needs of patients, drug formulators, pharmaceutical manufacturing commercial teams, and the environment must all be carefully balanced while employing established and trusted processes to minimize the barriers to entry for these devices.
The speaker will also demonstrate how Phillips-Medisize and Subcuject are engaged to address these challenges with a novel, cost-effective device that requires no battery, motor, or electronics.
Register now to access the recording of this webinar.
Wearable Bolus Injectors: Balancing Stakeholder Needs and Overcoming Barriers to Entry
Webinar Hosted by Xtalks
Wearable Injectors to Support Connected Health
As adoption of Connected Health systems increase, emerging technologies and platforms will be developed to address the most critical gaps in our existing healthcare infrastructure: telehealth for congestive heart failure, home healthcare for veterans, access to specialty physicians and continuity of care with primary care providers, remote intensive care, and medication adherence. Further, increased mental health support, with accompanying medication adherence, will be critical to patients as a new normal is achieved following the outbreak of COVID-19.
Wearable Injectors & Telehealth
Wearable injectors are quickly becoming a meaningful alternative for patients in their home environments. See how Phillips-Medisize’s technology platforms not only help achieve efficacy, but also minimize incremental cost increases to pharmaceutical companies, healthcare payers, and patients.